A fresh discovery by a team of researchers at the Weill Cornell Medical College has paved the way for a number of potential new drug targets to aid with the prevention and perhaps treatment of type 2 diabetes . Scientists at the college highlighted a key protein that influences the take up of glucose by cells.
The senior researcher on the study, Dr. Timothy McGraw, reportedly commented: “Glucose gets into muscle and fat cells assisted by a special transporter called GLUT4. In our study, when the protein (Rab10) was eliminated or its activity switched off, insulin was no longer able to properly trigger the recruitment of the GLUT4 glucose transporter to the surface of cells.”
McGraw reportedly concluded: “The recruitment of GLUT4 to the cell surface increases glucose movement from the blood into cells, where the glucose is stored for future use. Thus, Rab10 is involved in the insulin regulation of blood glucose levels. A disruption in the regulation of blood glucose levels, a condition called ‘insulin insensitivity,’ is a hallmark of type 2 diabetes, a disease that affects nearly 20 million Americans.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…